Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Current Liabilities for the quarter ending September 30, 2024: USD 60.81 M

Evolus, Inc. Current Liabilities is USD 60.81 M for the quarter ending September 30, 2024, a 25.29% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Evolus, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 48.54 M, a -5.33% change year over year.
Evolus, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 51.27 M, a -28.09% change year over year.
Evolus, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 71.30 M, a 461.04% change year over year.
Evolus, Inc. Current Liabilities for the quarter ending September 30, 2020 was USD 12.71 M, a -51.07% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGM: EOLS

Evolus, Inc.

CEO	Mr. David Moatazedi
IPO Date	Feb. 8, 2018
Location	United States
Headquarters	520 Newport Center Drive
Employees	322
Sector	Consumer Discretionary
Industries Cosmetics Dental Care Eyewear Personal Care

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key trends

Past 5 years